FDA Approves Dual Immunotherapy Combo: Tecvayli + Darzalex Faspro Transforms RRMM Treatment

　　On March 5,2026,the FDA approved Teclistamab(Tecvayli)in combination with Daratumumab and hyaluronidase(Darzalex Faspro)for adult patients with relapsed or refractory multiple myeloma(RRMM)who have received at least one prior therapy and are refractory to proteasome inhibitors and immunomodulatory agents.Concurrently,the FDA converted the accelerated approval of Teclistamab monotherapy to traditional approval,solidifying its role in this challenging patient population.

　　1.Development&Mechanism:

　　Developed by Janssen Biotech,Teclistamab is a BCMA/CD3 bispecific antibody designed to engage both the B-cell maturation antigen(BCMA)on myeloma cells and the CD3 receptor on T cells,activating T-cell-mediated tumor killing.Darzalex Faspro,a subcutaneous formulation of daratumumab,targets CD38 to enhance immune clearance.Together,this“dual-targeted immune activation”strategy synergizes to potentiate antitumor efficacy.

　　2.Defining RRMM:A Critical Challenge

　　Multiple myeloma is a plasma cell malignancy characterized by bone pain,anemia,renal impairment,hypercalcemia,and recurrent infections.Despite treatment advances,most patients relapse or become refractory,making RRMM a high unmet need in hematologic oncology.

　　3.Pivotal Trial:MajesTEC-3(NCT05083169)

　　The FDA approval was based on the global,randomized,open-label Phase 3 MajesTEC-3 trial,which enrolled 587 RRMM patients.Patients were randomized 1:1 to:

　　●Teclistamab+Darzalex Faspro(n=291)

　　●Control arm(daratumumab+pomalidomide/dexamethasone[DPd]or daratumumab+bortezomib/dexamethasone[DVd],n=296).

　　Key Trial Outcomes:

　　●Progression-Free Survival(PFS):Median PFS was Not Reached(NR)in the combo arm vs 18.1 months in control(HR=0.17;p<0.0001),reducing disease progression/death risk by 83%.

　　●Overall Survival(OS):OS was immature but favored the combo(HR=0.46 for death),indicating a survival benefit.

　　●Objective Response Rate(ORR):73.2%vs 42.6%(CR/sCR:28.5%vs 9.1%),highlighting deep and durable responses.

　　4.Safety&Risk Management:

　　The label includes a Boxed Warning for cytokine release syndrome(CRS)and neurotoxicity(including immune effector cell-associated neurotoxicity syndrome[ICANS]).Treatment must be administered through the Tecvayli-Talvey REMS program.Common adverse reactions(≥20%)include hypogammaglobulinemia,infections(e.g.,pneumonia),fatigue,diarrhea,pyrexia,and injection-site reactions.Robust infection monitoring and toxicity grading strategies are essential.

　　5.Clinical Impact&Future Directions

　　This approval establishes bispecific BCMA/CD3 therapy as a backbone strategy in RRMM,particularly in multiply-relapsed settings.The combo’s PFS and OS improvements represent a significant advancement,offering a viable option where treatment options are scarce.Ongoing research will likely explore earlier-line applications and combinations to further optimize outcomes.